NEW

Switch to Dark

Pricing

Learn

ZTS - Zoetis Inc

350

$115.62

$0.16 (0.139%)

At market close

$115.64

$0.02 (0.017%)

After Hours 3/13/26, 8:03 PM

4.22/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

ZTS

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Key Data & Metrics

Market Cap

$48.81B

Industry

Pharmaceuticals

EPS (TTM)

$6.09

P/E (TTM)

18.26

Div & Yield

$2.12 (1.83%)

FCF Payout Ratio

39.20%

P/S (TTM)

5.16

P/B

14.65

Diluted Shares

438.54M

Ex-Dividend

2026-04-20

Next Earnings

05-04

Forward P/E

16.71

Payout Ratio

33.48%

P/FCF (TTM)

21.38

FCF Yield

4.68%

Earnings Yield

5.48%

52 Week Range

Score Card

Explore Scores Tab

4.22

Very Good

Zoetis Inc has grown revenue at 2.28% over the past year, which suggests sales are increasing. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

5.00

Very Good

Management

3.00

Average

Growth

5.00

Very Good

Profitability

1.00

Very Bad

Fin. Health

5.00

Very Good

Dividends

1.00

Very Bad

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 16:20:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:59

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:52

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:45

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:27

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:22

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:16

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:10

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:31:04

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-23 16:30:56

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-01

High:

$210.00

81.6%

Avg:

$159.46

37.9%

Low:

$131.30

13.6%

(% change is relative to the current stock price: $115.62)

Analyst Recommendations

Go to Analyst Tab

3.88

Good

24%

Strong Buy (6)

40%

Buy (10)

36%

Hold (9)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.zoetis.com/
Address
10 Sylvan Way, Parsippany NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1555280

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

IPO Date

2013-02-01

Industry

Pharmaceuticals

Total Employees

14,500

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences